Science and Research

A Phase III, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY TM Study)

To demonstrate superiority of BI 1291583 compared to placebo on the primary endpoint, the annualised rate of adjudicated pulmonary exacerbations in participants with bronchiectasis

Study details
Study-ID: 2024-518589-29
Study-ID: 2024-518589-29
DZL Disease Area: CFBE
DZL Disease Area: CFBE
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL on steering board
DZL Role: DZL on steering board
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: ARCN, BREATH, CPC-M, BIH / Charité - Associated Partner
DZL Participating Sites: ARCN, BREATH, CPC-M, BIH / Charité - Associated Partner
Start Date: 25.08.2025
Completion Date: 31.12.2030
Status: Recruiting
Status: Recruiting
DZL on steering board
Link to Study


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.